menu
    • menu
    [{"orgOrder":0,"company":"POP Biotechnologies","sponsor":"EuBiologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"EuCorVac-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"POP Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"POP Biotechnologies \/ EuBiologics","highestDevelopmentStatusID":"10","companyTruncated":"POP Biotechnologies \/ EuBiologics"},{"orgOrder":0,"company":"POP Biotechnologies","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Funding","leadProduct":"Padivax","moa":"Amyloid-beta\/Tau","graph1":"Neurology","graph2":"Preclinical","graph3":"POP Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"POP Biotechnologies \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"POP Biotechnologies \/ National Institutes of Health"}]

    Find Clinical Drug Pipeline Developments & Deals by POP Biotechnologies

    Menu

    POP Biotechnologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            POP Biotechnologies

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            POP Biotechnologies

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Padivax

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $2.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            POP Biotechnologies Awarded $2.46M NIH Grant for Alzheimer's Immunotherapy

                            Details : The technology is based on displaying the Aβ and phospho-tau targets in a mosaic-like fashion on the surface of nanoparticles.

                            Product Name : Padivax

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 01, 2025

                            Lead Product(s) : Padivax

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $2.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            POP Biotechnologies

                            U.S.A arrow
                            Pharmtech Exhibition
                            Not Confirmed

                            POP Biotechnologies

                            U.S.A arrow
                            Pharmtech Exhibition
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EuCorVac-19

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : EuBiologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            POP Biotechnologies and EuBiologics' EuCorVac-19 COVID-19 Vaccine Hits Target in Phase 3 Trial

                            Details : EuCorVac-19, a recombinant protein vaccine displaying the SARS-CoV-2 receptor-binding domain (RBD) antigen on the immunogenic liposomes, which is present top line interim results of a Phase 3 clinical trial.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            July 14, 2023

                            Lead Product(s) : EuCorVac-19

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : EuBiologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth